Firefly Neuroscience, Inc. (NASDAQ:AIFF) shares are trading higher Thursday after the company announced a public-private partnership with the Department of Defense.
- Firefly shares are climbing with conviction. What’s behind AIFF gains?
Department Of Defense Partnership Expands Commercial Footprint
Firefly said the partnership will support the assessment and treatment of active-duty U.S. service members and veterans suffering from post-traumatic stress disorder and traumatic brain injury.
The company's FDA 510(k)-cleared, AI-powered EEG/ERP platform is being deployed across related Department of Defense programs, providing healthcare providers with objective neurological data to support diagnosis, treatment planning and outcomes tracking. The platform is designed to be non-invasive and scalable across both clinical and operational environments.
The partnership represents an expansion of Firefly's commercial footprint into the U.S. government and defense health sectors and is expected to serve as a potentially significant channel for the company's broader commercial strategy.
"We believe that this ongoing strategic partnership positions us well to benefit from the significant and growing U.S. government investment in military brain health — with a validated, FDA-cleared platform," said CEO Greg Lipschitz.
Firefly Shares Soar
AIFF Price Action: At the time of publication, Firefly shares are trading 38.69% higher at $2.33, according to data from Benzinga Pro.
Image via Shutterstock
Login to comment